Foundayo vs Rybelsus

Peptide versus small molecule

Semaglutide is a chain of amino acids, and the gut exists to break those down. Rybelsus gets around that by pairing each tablet with 300 mg of SNAC, salcaprozate sodium, which raises pH locally in the stomach so a sliver of the dose crosses the lining before it is destroyed. The label puts absolute bioavailability at 0.4% to 1%. Food, a large glass of water, or another pill taken at the same time all cut that further, which is where the fasting rules come from.

Orforglipron is not a peptide. It is a conventional drug molecule, about 900 daltons, that activates the same GLP-1 receptor. It survives digestion on its own. The Foundayo label reports 77% bioavailability, a peak at 4 to 8 hours, and steady state after about a week. With food, exposure fell 19% in the label’s study and about 18% to 24% in the published food-effect trials, which the label calls not clinically relevant. So the instruction is one line: once daily, with or without food, swallow whole.

The head-to-head

ACHIEVE-3 randomised 1,698 adults with type 2 diabetes inadequately controlled on metformin to orforglipron 12 or 36 mg or oral semaglutide 7 or 14 mg for 52 weeks. It was open-label. Orforglipron won on the primary endpoint at every pairing, including its lower dose against semaglutide’s higher one.

Weight followed the same pattern: 9.2% on orforglipron 36 mg and 6.7% on 12 mg, against 5.3% on semaglutide 14 mg and 3.7% on 7 mg.

The cost showed up in the safety table. Gastrointestinal adverse events hit 58% to 59% of the orforglipron groups versus 37% to 45% on semaglutide. Discontinuation for adverse events was 9% to 10% versus 4% to 5%. Pulse rose by 3.7 to 4.7 beats per minute on orforglipron versus 1.0 to 1.5 on semaglutide. Within one trial, the larger effect came with more side effects. Whether that reflects the molecule or simply the exposure achieved is not something ACHIEVE-3 can separate, and absorption figures do not carry across two different molecules.

One caveat that matters. ACHIEVE-3 is a diabetes trial, and Foundayo is not approved for diabetes. It is the cleanest evidence that the two molecules differ, but it is not evidence for either product’s approved use against the other.

What each one is approved for

Foundayo is approved for weight reduction in adults with obesity, or overweight with a weight-related condition. The evidence is ATTAIN-1, 3,127 adults without diabetes over 72 weeks, and ATTAIN-2, 1,613 adults with type 2 diabetes.

In ATTAIN-1, 54.6% of the 36 mg group lost at least 10% of body weight and 18.4% lost at least 20%, against 12.9% and 2.8% on placebo. In ATTAIN-2, the same dose produced 9.6% weight loss versus 2.5%, the familiar blunting that diabetes causes with every GLP-1. Discontinuation for adverse events ran 5% to 10% across both trials.

Rybelsus is approved for type 2 diabetes. Its evidence is the PIONEER program. In PIONEER 4, 14 mg lowered HbA1c by 1.2 points over 26 weeks, matching injected liraglutide, with 4.4 kg of weight loss. Higher tablets exist: in PIONEER PLUS, 25 and 50 mg beat 14 mg on HbA1c, and the 25 mg tablet reached the market as Wegovy, not Rybelsus, on the strength of OASIS 4. Rybelsus itself has no weight-loss indication. It does, since October 2025, carry a cardiovascular risk-reduction indication from SOUL: major events 12.0% versus 13.8% on placebo in 9,650 adults with type 2 diabetes and cardiovascular or kidney disease, hazard ratio 0.86.

Orforglipron’s diabetes data are just as extensive. ACHIEVE-1 tested it as monotherapy in 559 adults with early type 2 diabetes: HbA1c fell 1.24 to 1.48 points over 40 weeks against 0.41 on placebo, with 7.6% weight loss at the top dose. That indication is not on the label yet.

One tablet, two sets of numbers

The trial papers describe orforglipron as 3, 6, 12, and 36 mg. The box says 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. Lilly’s later analyses report the ATTAIN arms as 5.5, 9, and 17.2 mg: the commercial tablet is a different formulation from the one used in the trials, labelled by a different dose convention, with exposure matched to the trial arms. When this page cites 36 mg, it is describing the arm that corresponds to the 17.2 mg tablet.

The dose ladders

Both ladders move on a 30-day cadence, unusual for daily drugs. Neither is limited by how fast the drug accumulates; orforglipron reaches steady state in about a week. The interval is about letting the gut adapt.

Which comparison you wanted

• The semaglutide tablet against the semaglutide injection: Ozempic vs Rybelsus.
• How oral and injected GLP-1s differ in general: oral vs injectable GLP-1.
• What Foundayo is: what is Foundayo.
• What a peptide is, and why orforglipron is not one: what is a peptide.

For the log, a tablet has no injection site, so the useful fields are the time taken and, for Rybelsus, how long before breakfast. How GLP-1 tracking works covers both.

7. Foundayo vs Rybelsus FAQ

• Is Foundayo better than Rybelsus?

  In the one head-to-head trial, ACHIEVE-3, orforglipron lowered HbA1c and weight more than oral semaglutide over 52 weeks, with more gastrointestinal side effects and more discontinuations. But the two are approved for different things: Foundayo for weight reduction, Rybelsus for type 2 diabetes. Which is appropriate is a prescriber's decision.

• Why can Foundayo be taken with food and Rybelsus cannot?

  Orforglipron is a small molecule that survives digestion; the label reports 77% bioavailability and only a modest drop with food. Bioavailability explains the dosing rules, not the trial result; the head-to-head difference comes from ACHIEVE-3, not from absorption arithmetic. Semaglutide is a peptide that the gut destroys, so Rybelsus relies on an absorption enhancer, SNAC, that only works on an empty stomach with a small volume of water. The label puts its bioavailability at 0.4% to 1%.

• Can Rybelsus be used for weight loss?

  Weight reduction is not on the Rybelsus label, and its 3, 7, and 14 mg doses have not been tested for it. Oral semaglutide at 25 mg was, in OASIS 4, and that dose is sold as a Wegovy tablet, not as Rybelsus.

• Can Foundayo be used for type 2 diabetes?

  Not on the current label, which covers weight reduction only. Orforglipron has completed diabetes trials, ACHIEVE-1 through ACHIEVE-3, so a diabetes indication may follow. This page does not predict approvals.

• What is the difference between a peptide and a small-molecule GLP-1?

  A peptide GLP-1 such as semaglutide is a chain of amino acids that mimics the hormone. A small-molecule GLP-1 such as orforglipron is a conventional drug molecule that activates the same receptor without being a peptide. The practical consequences are oral absorption, no refrigeration, and cheaper manufacturing.

8. Sources